This disclosure relates to methods of treating or preventing cancer comprising administering an effective amount of a glutamate dehydrogenase 1 inhibitor to a subject in need thereof. In certain embodiments, the inhibitor has Formula I: ##STR00001## prodrugs, derivatives, or salts thereof wherein the substituents are reported herein. In certain embodiments, the inhibitor is purpurin, derivative, or salt thereof. In certain embodiments, the inhibitor is 2-allyl-1-hydroxyanthracene-9,10-dione, prodrugs, derivatives, or salts thereof.

Emory University

Glutamate dehydrogenase 1 inhibitors and methods of treating cancer

A novel pathway in cancer cell metabolism is identified. Targeting of any gene, protein, or enzyme that modulates activity or flux through this pathway, including, but not limited to IDH1, isocitrate dehydrogenase 2 (IDH2), aconitase 1 (ACO1), aconitase 2 (ACO2), glutaminase (GLS), glutamate dehydrogenase (GDH) and transaminase, provides effective means of inhibiting tumor growth.

Stephanopoulos; Gregory

Metallo; Christian M.

Kelleher; Joanne K.

Iliopoulos; Othon

da Costa Gameiro Guerreiro; Paulo Alexandre

Massachusetts Institute of Technology

The General Hospital Corporation

Metabolic gene, enzyme, and flux targets for cancer therapy

glutamate dehydrogenase

vėžys

neoplasms

glutamate dehydrogenase/vėžys

Glutamate dehydrogenase 1 inhibitors and methods of treating cancer

Metabolic gene, enzyme, and flux targets for cancer therapy

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu